Verifiedmarketreports.com has announced the addition of the “Global Hemophilia Gene Therapy Market Research Report” The report focuses on global major leading players with information such as company profiles, product picture and specification.
Pune, India -- (SBWIRE) -- 04/13/2019 -- Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
Key players in details:
Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics and Others.
The global Hemophilia Gene Therapy market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024, according to recent research.
For More information Register free sample copy of this report here:
https://www.verifiedmarketreports.com/download-sample/?rid=41592&mode=BRG10
Market is segmented on the basis Type, Application and Region:
Global Hemophilia Gene Therapy Market segment by type: Hemophilia A, Hemophilia B.
Global Hemophilia Gene Therapy Market Segment by Applications: Hemophilia A Gene Therapy, Hemophilia B Gene Therapy.
Scope of the Report:
About 80% of them have hemophilia A, which affects the clotting factor VIII. The second most common form, hemophilia B, is due to a deficiency of the clotting factor IX. Several biotechs are racing to launch the first gene therapy for hemophilia. Currently, uniQure in the Netherlands and Spark Therapeutics in the US have the most advanced programs.
Spark scored a victory in December when it presented Phase I/II for its candidate SPK-9001. The gene therapy was able to reduce annual bleeding episodes by 97%, as compared to its competitor uniQure's candidate, AMT-060. However, uniQure has fought back. The company added a modification in its gene therapy that is known to increase clotting activity by 8- to 9- fold. This improved version has already been cleared to start a Phase III clinical trial in both Europe and the US.
Hemophilia Gene Therapy Market report comprises key factor which can be useful for any new player in the industry. It is possible due to comparative analysis and overview that is provided in the report. By focusing on all the details in the report, it is more than enough for any newcomers entering the industry so that they can get a better knowledge and study the market before making any strategic decision.
To know more about this report:
https://www.verifiedmarketreports.com/product/global-hemophilia-gene-therapy-market-2019-by-company-regions-type-and-application-forecast-to-2024/?mode=BRG10
Geographically, this report is segmented into several key Regions, with Sales, Sales, revenue, Market Share (%) and Growth Rate (%) of product in these regions, from 2017 to 2024 (forecast), covering United States, North America (Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Columbia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa), RoW (Rest of World).
There are 15 Chapters to deeply display the global Hemophilia Gene Therapy market:
Chapter 1, to describe Hemophilia Gene Therapy Market Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Hemophilia Gene Therapy, with sales, revenue, and price of Hemophilia Gene Therapy Market, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Hemophilia Gene Therapy, for each region, from 2013 to 2019;
Chapter 5, 6, 7, 8 and 9, to analyze the Hemophilia Gene Therapy Market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2019;
Chapter 12, Hemophilia Gene Therapy market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024;
Chapter 13, 14 and 15, to describe Hemophilia Gene Therapy Market sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Avail Discount for this report at:
https://www.verifiedmarketreports.com/ask-for-discount/?rid=41592&mode=BRG10
About Verified Market Reports
Verified Market Reports is part of the Verified Market Research which offers premium reports from over hundreds of top publishers worldwide. It has the most widespread collection of market research reports, analysis & forecast data for businesses and governments. We update and improve our repository routinely to deliver instant online access to the world's most comprehensive and current database of expert insights.
Contact Us:
sales@verifiedmarketreports.com | +1 (704) 266-3234